M&A / Deals Otsuka grows in neuroplastogens with $1.225bn Transcend buy PharmaphorumOtsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.M&A / DealsNeuroscienceRead full story pharminent March 29, 2026 (Last updated: March 30, 2026) Pharmaphorum Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials. M&A / DealsNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly puts up to $2.75bn into Insilico allianceNext: Trustworthy AI in clinical oversight Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
